Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial
Ye Zhao, Xuewei Li, Yujing Zhou, Jin Gao, Yang Jiao, Baoli Zhu, Depei Wu, Xiaofei Qi, Ye Zhao, Xuewei Li, Yujing Zhou, Jin Gao, Yang Jiao, Baoli Zhu, Depei Wu, Xiaofei Qi
Abstract
Gastrointestinal (GI) tract graft-versus-host disease (GvHD) is a major cause of post-allo-HSCT (hematopoietic stem cell transplantation) morbidity and mortality. Patients with steroid-refractory GI-GvHD have a poor prognosis and limited therapeutic options. FMT2017002 trial (#NCT03148743) was a non-randomized, open-label, phase I/II clinical study of FMT for treating patients with grade IV steroid-refractory GI-GvHD. A total of 55 patients with steroid-refractory GI-GvHD were enrolled in this study. Forty-one patients with grade IV steroid-refractory GI-GvHD were included in the final statistical analysis. Of them, 23 patients and 18 patients were assigned to the FMT group and the control group, respectively. On days 14 and 21 after FMT, clinical remission was significantly greater in the FMT group than in the control group. Within a follow-up period of 90 days, the FMT group showed a better overall survival (OS). At the end of the study, the median survival time was >539 days in the FMT group and 107 days in the control group (HR=3.51; 95% CI, 1.21-10.17; p=0.021). Both the event-free survival time (EFS) (HR=2.3, 95% CI, 0.99-5.4; p=0.08) and OS (HR=4.4, 95% CI, 1.5-13.04; p=0.008) were higher in the FMT group during the follow-up period. Overall, the mortality rate was lower in the FMT group (HR=3.97; 95% CI, 1.34-11.75; p=0.013). No differences in the occurrence of any other side effects were observed. Our data suggest that the diversity of the intestinal microbiota could be affected by allo-HSCT. Although its effectiveness and safety need further evaluation, FMT may serve as a therapeutic option for grade IV steroid-refractory GI-GvHD.
Clinical trial registration: [ClinicalTrials.gov], identifier [NCT03148743].
Keywords: clinical trials; diarrhea; fecal microbiota transplantations; graft-versus-host disease; refractory gastrointestinal.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Copyright © 2021 Zhao, Li, Zhou, Gao, Jiao, Zhu, Wu and Qi.
Figures
References
- Holtan SG, Pasquini M, Weisdorf DJ. Acute GVHD: A Bench to Bedside Update. Blood (2014) 124(3):363–73. 10.1182/blood-2014-01-514786
- Copelan EA. Hematopoietic Stem-Cell Transplantation. N Engl J Med (2006) 354(17):1813–26. 10.1056/NEJMra052638
- Qi X, Li X, Zhao Y, Wu X, Chen F, Ma X, et al. . Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study. Front Immunol (2018) 9:2195. 10.3389/fimmu.2018.02195
- McDonald GB. How I Treat Acute Graft-Versus-Host Disease of the Gastrointestinal Tract and the Liver. Blood (2016) 127(12):1544–50. 10.1182/blood-2015-10-612747
- Toubai T, Magenau J. Immunopathology and Biology-Based Treatment of Steroid-Refractory Graft-Versus-Host Disease. Blood (2020) 136(4):429–40. 10.1182/blood.2019000953
- Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. . First- and Second-Line Systemic Treatment of Acute Graft Versus Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 18(8):1150–63. 10.1016/j.bbmt.2012.04.005
- Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, et al. . Prognostic Factors and Outcomes of Severe Gastrointestinal GVHD After Allogeneic Hematopoietic Cell Transplantation. Bone Marrow Transplant (2014) 49(7):966–71. 10.1038/bmt.2014.69
- Köhler N, Zeiser R. Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD. Front Immunol (2019) 9:3179. 10.3389/fimmu.2018.03179
- Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The Human Microbiome Project. Nature (2007) 449:804–10. 10.1038/nature06244
- Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA, et al. . Regulation of Intestinal Inflammation by Microbiota Following Allogeneic Bone Marrow Transplantation. J Exp Med (2012) 209(5):903–11. 10.1084/jem.20112408
- Round JL, Mazmanian SK. The Gut Microbiota Shapes Intestinal Immune Responses During Health and Disease. Nat Rev Immunol (2009) 9(5):313–23. 10.1038/nri2515
- Penack O, Holler E, van den Brink MR. Graft-Versus-Host Disease: Regulation by Microbe-Associated Molecules and Innate Immune Receptors. Blood (2010) 115(10):1865–72. 10.1182/blood-2009-09-242784
- Buffie CG, Pamer EG. Microbiota-Mediated Colonization Resistance Against Intestinal Pathogens. Nat Rev Immunol (2013) 13(11):790–801. 10.1038/nri3535
- Spindelboeck W, Schulz E, Uhl B, Kashofer K, Aigelsreiter A, Zinke-Cerwenka W, et al. . Repeated Fecal Microbiota Transplantations Attenuate Diarrhea and Lead to Sustained Changes in the Fecal Microbiota in Acute, Refractory Gastrointestinal Graft-Versus-Host-Disease. Haematologica (2017) 102:e210–3. 10.3324/haematol.2016.154351
- Kakihana K, Fujioka Y, Suda W, Najima Y, Kuwata G, Sasajima S, et al. . Fecal Microbiota Transplantation for Patients With Steroid-Resistant Acute Graft-Versus-Host Disease of the Gut. Blood (2016) 28(16):2083–8. 10.1182/blood-2016-05-717652
- Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. . Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology (2015) 149(1):223–7. 10.1053/j.gastro.2015.05.008
- Weingarden AR, Vaughn BP. Intestinal Microbiota, Fecal Microbiota Transplantation, and Inflammatory Bowel Disease. Gut Microbes (2017) 8(3):238–52. 10.1080/19490976.2017.1290757
- Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. . Fecal Microbiota Transplant for Treatment of Clostridium Difficile Infection in Immunocompromised Patients. Am J Gastroenterol (2014) 109(7):1065–71. 10.1038/ajg.2014.133
- van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. . Duodenal Infusion of Donor Feces for Recurrent Clostridium Difficile. N Engl J Med (2013) 368(5):407–15. 10.1056/NEJMoa1205037
- Wardill HR, Secombe KR, Bryant RV, Hazenberg MD, Costello SP. Adjunctive Fecal Microbiota Transplantation in Supportive Oncology: Emerging Indications and Considerations in Immunocompromised Patients. EBioMedicine (2019) 44:730–40. 10.1016/j.ebiom.2019.03.070
- Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. . Severity Index for Grading Acute Graft-Versus-Host Disease: Retrospective Comparison With Glucksberg Grade. Br J Haematol (1997) 97(4):855–64. 10.1046/j.1365-2141.1997.1112925.x
- Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 15(6):825–28.
- Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, et al. . Step-Up Fecal Microbiota Transplantation Strategy: A Pilot Study for Steroid-Dependent Ulcerative Colitis. J Transl Med (2015) 13(1):298–309. 10.1186/s12967-015-0646-2
- Taur Y, Coyte K, Schluter J, Robilotti E, Figueroa C, Gjonbalaj M, et al. . Reconstitution of the Gut Microbiota of Antibiotic-Treated Patients by Autologous Fecal Microbiota Transplant. Sci Transl Med (2018) 10(460):eaap9489. 10.1126/scitranslmed.aap9489
- Weber D, Oefner PJ, Hiergeist A, Koestler J, Gessner A, Weber M, et al. . Low Urinary Indoxyl Sulfate Levels Early After Transplantation Reflect a Disrupted Microbiome and are Associated With Poor Outcome. Blood (2015) 126(14):1723–8. 10.1182/blood-2015-04-638858
- DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, et al. . Third-Party Fecal Microbiota Transplantation Following Allo-HCT Reconstitutes Microbiome Diversity. Blood Adv (2018) 2(7):745–53. 10.1182/bloodadvances.2018017731
- DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, et al. . Drug-Resistant E. Coli Bacteremia Transmitted by Fecal Microbiota Transplant. N Engl J Med (2019) 381(21):2043–50. 10.1056/NEJMoa1910437
Source: PubMed